MedTrace Logo

Survey Based Discrete Choice Experiment Study in Prostate Cancer (DECIDER) Study

NCT05381311 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1020

Last updated 2024-11-21

No results posted yet for this study

Summary

The purpose of this study is to quantify and publish participants' relative preferences for outcomes of chemotherapy and novel oral hormonal agents when added to androgen deprivation therapy (ADT) for participants with locally-advanced and metastatic hormone-sensitive prostate cancer (mHSPC). This study will also quantify the importance of administration factors related to convenience relative to treatment outcomes.

Conditions

Sponsors & Collaborators

  • Astellas Pharma Global Development, Inc.

    lead INDUSTRY

Principal Investigators

  • Astellas Pharma Global Development, Inc. · Astellas Pharma Global Development, Inc.

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-03
Primary Completion
2022-12-11
Completion
2022-12-11

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05381311 on ClinicalTrials.gov